Skip to content

Mother-to-child Transmission of HBV in China

A Real World, Multi-center Study on Mother-to-child Transmission of Hepatitis B Virus in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05172453
Enrollment
50000
Registered
2021-12-29
Start date
2015-07-01
Completion date
2025-12-31
Last updated
2021-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Chronic, Mother to Child Transmission

Keywords

hepatitis B, mother-to-child transmission

Brief summary

In order to evaluate the feasibility of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030, a multi-center, prospective cohorts study was conducted to investigate MTCT of HBV in China.

Detailed description

A prospective, multicenter study of pregnant women with HBV infection was conducted from July 2015 up to now in a real world setting in the Shield Project stage Ⅱ. Inclusion criteria was any pregnant women with chronic HBV infection. Pregnant women were excluded if they had a positive serologic test for human immunodeficiency virus or hepatitis C virus or any co-morbidity that might reduce compliance or if they were unable or unwilling to use the mobile health application-Shield APP. Enrolled mothers and infants were prospectively followed until infant post-vaccination serologic testing (PVST) was performed at 7-12 months of age. Demographic data, antiviral treatment history, pregnancy and labour history, co-morbidity, HBV serologic marker tests, HBV DNA tests, liver function tests, mode of delivery, neonatal characteristics (height, weight, head circumference, Apgar score and any major birth defect), breastfeeding and PVST for infants at 7-12 months of age were collected. A mobile health application called SHIELD was developed and used in the Shield Project stage Ⅱ to collect data and provide support for communication between mothers and their doctors. All laboratory test reports, questionnaires and other relevant information was uploaded into SHIELD. Participants could consult with their doctors via SHIELD during the follow-up.

Interventions

OTHERcomprehensive management algorithm for preventing mother-to-child transmission of HBV

To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents.

Sponsors

Chinese Foundation for Hepatitis Prevention and Control
CollaboratorUNKNOWN
Tigermed Consulting Co., Ltd
CollaboratorINDUSTRY
Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* pregnant women with chronic HBV infection.

Exclusion criteria

* positive serologic test for human immunodeficiency virus or hepatitis C virus; * any co-morbidity that might reduce compliance; * unable or unwilling to use the mobile health application-Shield APP

Design outcomes

Primary

MeasureTime frameDescription
rate of mother-to-child transmission of HBV5 yearscompare rate of mother-to-child transmission of HBV among children born to mothers with and without antiviral therapy during pregnancy
rate of birth defect5 yearscompare rate of birth defect among children born to mothers with and without antiviral therapy during pregnancy

Secondary

MeasureTime frameDescription
change of HBV DNA level in mothers with antiviral therapy from baseline to withdrawal of antiviral drugsfrom enrollment to delivery, assessed up to 40 weekscompare HBV DNA levels of mothers with antiviral therapy at baseline and after delivery

Countries

China

Contacts

Primary ContactJinlin Hou
jlhousmu@163.com+86 13802727354
Backup ContactZhihua Liu
zhihualiu@126.com+8618665000386

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026